TG Therapeutics Inc at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript
Good afternoon, everyone, and good morning for folks here on the West Coast. So for our next fireside chat, we are delighted to welcome Mike Weiss, the CEO of TG Therapeutics.
Thanks, Mike, for being here today. I know you have a lot going on, but obviously, the focus for today would be ublituximab in RMS.
But obviously, there is a lot that has changed in the story just in the past two quarters. So maybe just help us understand how should we think about TG, where we stand, and then we will get into sort of very steady progresses in the coming months.
Yeah, sure. Great to see you and thanks for having us. So yeah, I think I heard you say a lot of things have changed in the last two quarters. I think most of it has happened in the last two weeks. So it's been a pretty aggressive change of course.
Unfortunately, as you know and sure most of the viewers know, we ran into a bit of a challenge for our CLL application,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |